Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic and benign disorders

Mod Pathol. 2005 Dec;18(12):1550-61. doi: 10.1038/modpathol.3800480.

Abstract

Spleen is a common site of extramedullary hematopoiesis. Extramedullary hematopoiesis seen in non-neoplastic conditions can occasionally be extensive and raise concerns for a myeloid neoplasm. We compared the morphologic and immunohistochemical features of splenic hematopoietic proliferations seen in neoplastic myeloid disorders (eg chronic myeloproliferative disorders, myelodysplastic/myeloproliferative disorders and acute myeloid leukemias) to extramedullary hematopoiesis seen in a variety of reactive conditions. In all, 80 spleen specimens were reviewed. The presence of each marrow-derived lineage, dysplasia and immunohistochemical results were evaluated (CD34, CD117, myeloperoxidase, CD68, p53, TdT, CD42b and hemoglobin). Neoplastic hematopoietic proliferations in chronic myeloproliferative disorders are characterized by trilineage hematopoiesis with significant dysplasia in all cell lineages. Acute myeloid leukemia showed an increase in immature forms, which were highlighted by immunohistochemistry. Reactive extramedullary hematopoiesis showed variability in histologic features. Post-bone marrow transplant and thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome spleens showed extramedullary hematopoiesis with some morphologic features of immaturity, which could simulate chronic myeloproliferative disorder. However, they lacked characteristic immunohistochemical features of neoplastic myeloid disorders such as positivity for CD34 or CD117.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / metabolism
  • Bone Marrow / metabolism
  • Bone Marrow / pathology*
  • Bone Marrow Neoplasms / metabolism
  • Bone Marrow Neoplasms / pathology*
  • Cell Proliferation
  • Child
  • Child, Preschool
  • Hematopoiesis, Extramedullary*
  • Humans
  • Middle Aged
  • Myeloproliferative Disorders / metabolism
  • Myeloproliferative Disorders / pathology*
  • Spleen / metabolism
  • Spleen / pathology*

Substances

  • Biomarkers, Tumor